The vaccine candidate therefore does not at this stage reach the required threshold of 50% efficacy.
Reading time : 1 min.
The vaccine developed by the German laboratory CureVac is only 48% effective in preventing Covid-19, according to full results from a large-scale clinical trial, the company announced on Wednesday June 30 in a press release. ). This rate is much lower than other already approved messenger RNA vaccines, namely products from Pfizer / BioNTech and Moderna.
Among trial participants, “the CVnCoV vaccine candidate demonstrated an overall efficacy of 48% (83 cases in the vaccinated group, 145 in the placebo group) against Covid-19 disease, regardless of its severity”, detailed the laboratory. The vaccine candidate therefore does not at this stage reach the threshold of 50% efficacy required by the European health authorities. Curevac signed with the European Union a contract for the purchase of 405 million doses.